Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,114 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neck Cancer Clear all
Not yet recruiting Not applicable Interventional

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy

NCT07885033
View directory record Official record
Conditions
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy, Radiation Toxicity
Interventions
ORAL CARE PRODUCT KIT
Other
Lead sponsor
UNCANCER LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 3:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Not applicable Interventional

Studying Survivorship Care Plans in Head and Neck Cancer

NCT03106090
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
educational materials
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 27, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

NCT07631650
View directory record Official record
Conditions
Head and Neck Disorder, Head and Neck Cancer
Interventions
Bevonescein (ALM 488) Infusion
Drug
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 3:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 2 Interventional

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

NCT00006033
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene therapy, interleukin-2 gene, methotrexate
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

NCT01034358
View directory record Official record
Conditions
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 2 Interventional

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

NCT00021333
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 2 Interventional

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

NCT00004233
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, triacetyluridine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

NCT00750555
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
Interventions
motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

NCT00703976
View directory record Official record
Conditions
Cancer
Interventions
Bevacizumab, Cetuximab, Pemetrexed, Radiation therapy
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Not applicable Interventional Results available

Improving Goals of Care Discussion in Advanced Cancer Patients

NCT02374255
View directory record Official record
Conditions
Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions
GoC intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
TPX-0046
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
20
States / cities
La Jolla, California • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 27, 2026, 3:17 PM EDT
Recruiting No phase listed Observational

Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

NCT03676647
View directory record Official record
Conditions
Thyroid Gland Nodule
Interventions
Diagnostic DNA Methylation Signature
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 3:17 PM EDT
Active, not recruiting No phase listed Observational

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT04574635
View directory record Official record
Conditions
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma, Stage I Cervical Cancer FIGO 2018, Stage IA Cervical Cancer FIGO 2018, Stage IA1 Cervical Cancer FIGO 2018, Stage IA2 Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IV Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IVB Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

NCT00185835
View directory record Official record
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell
Interventions
ZD-1839, Cisplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Phase 1Phase 2 Interventional

A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

NCT00154089
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
EM-1421
Drug
Lead sponsor
Erimos Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Phase 1 Interventional Results available

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

NCT04144140
View directory record Official record
Conditions
Lymphoma, Advanced Solid Tumors
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 27, 2026, 3:17 PM EDT
Completed Not applicable Interventional

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

NCT04284540
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Adjuvant hypofractionation, Definitive Hypofractionation
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
70 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 3:17 PM EDT
Active, not recruiting Phase 2 Interventional

Induction Chemotherapy for Locally Advanced Esophageal Cancer

NCT03110926
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
mFOLFOX6, Chemoradiation
Drug · Combination Product
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated Not applicable Interventional Results available

Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy

NCT04585243
View directory record Official record
Conditions
HPV
Interventions
Evalyn Brush
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 27, 2026, 3:17 PM EDT
Terminated No phase listed Observational

Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck

NCT00797043
View directory record Official record
Conditions
Malignant Neoplasm of Skin Head and Neck
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 27, 2026, 3:17 PM EDT